Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Psoriatic patients underdiagnosed, undertreated for hypertension and dyslipidaemia

08 Mar 2018

There appear to be several patients with psoriasis and psoriatic arthritis (PsA) who are underdiagnosed and undertreated for hypertension and dyslipidaemia in actual situations, a recent study has found.

Overall, 2,254 patients (58.9 percent PsA; 41.1 percent psoriasis; mean age 52 years; 53 percent men) from eight centres in Canada, Israel and the United States were included in this study.

Of the participants, 87.6 percent had at least one modifiable cardiovascular risk factor (CVRF), 45.1 percent had hypertension, 49.4 percent dyslipidaemia, 13.3 percent diabetes, 75.3 percent were overweight or obese, 54.3 percent had central obesity, and 17.3 percent were current smokers.

There were 59.2 percent and 65.6 percent of patients with hypertension and dyslipidaemia, respectively, who were undertreated. Moreover, undertreatment correlated with younger age (≤50 years), having psoriasis and male sex.

To estimate the number of underdiagnosis and undertreatment of CVRF in an international multicentre cohort of patients with psoriasis and PsA, researchers conducted a cross-sectional of patients with psoriatic disease form the International Psoriasis and Arthritis Research Team cohort. They determined the presence of modifiable CVRF (diabetes, hypertension, dyslipidaemia, smoking, elevated body mass index and central obesity) and the use of appropriate therapies for hypertension and dyslipidaemia.

The Framingham Risk Score was used to calculate the 10-year CV risk. Physician adherence with guidelines for the treatment of hypertension and dyslipidaemia was also evaluated. Finally, researchers used regression analysis to assess predictors of undertreatment of hypertension and dyslipidaemia.

“Strategies to improve the management of CVRF in psoriatic patients are warranted,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.